• 1
    Kerr T., Tyndall M., Li K., Montaner J., Wood E. Safer injection facility use and syringe sharing in injection drug users. Lancet 2005; 366: 3168.
  • 2
    Milloy M. J., Kerr T., Tyndall M., Montaner J., Wood E. Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility. PLoS One 2008; 3: e3351.
  • 3
    Kerr T., Montaner J., Wood E. Supervised injecting facilities: time for scale-up? Lancet 2008; 372: 3545.
  • 4
    Wood E., Tyndall M. W., Zhang R., Stoltz J. A., Lai C., Montaner J. S. et al. Attendance at supervised injecting facilities and use of detoxification services. N Engl J Med 2006; 354: 25124.
  • 5
    Salmon A., Van Beek I., Amin J., Kaldor J., Maher L. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia. Addiction 2010; 105: 67683.
  • 6
    Bayoumi A., Zaric G. The cost-effectiveness of Vancouver's supervised injection facility. Can Med Assoc J 2008; 179: 114351.
  • 7
    Des Jarlais D. C., Arasteh K., Semaan S., Wood E. HIV among injecting drug users: current epidemiology, biologic markers, respondent-driven sampling, and supervised-injection facilities. Curr Opin HIV AIDS 2009; 4: 30813.
  • 8
    Hendrich D. European Report on Drug Consumption Rooms. Lisbon, Portugal. European Monitoring Centre for Drugs and Drug Addiction; 2004.
  • 9
    Shannon K., Ishida T., Morgan R., Bear A., Oleson M., Kerr T. et al. Potential community and public health impacts of medically supervised safer smoking facilities for crack cocaine users. Harm Reduct J 2006; 3: 1.
  • 10
    Collins C. L., Kerr T., Kuyper L. M., Li K., Tyndall M. W., Marsh D. C. et al. Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use. J Urban Health 2005; 82: 27684.
  • 11
    Collins C. L., Kerr T., Tyndall M. W., Marsh D. C., Kretz P. S., Montaner J. S. et al. Rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users. Can J Public Health 2005; 96: 3447.
  • 12
    Edlin B. R., Irwin K. L., Faruque S., McCoy C. B., Word C., Serrano Y. et al. Intersecting epidemics—crack cocaine use and HIV infection among inner-city young adults. Multicenter crack cocaine and HIV infection study team. N Engl J Med 1994; 331: 14227.
  • 13
    McMahon J. M., Tortu S. A potential hidden source of hepatitis C infection among noninjecting drug users. J Psychoact Drugs 2003; 35: 45560.
  • 14
    Patterson T. L., Semple S. J., Staines H., Lozada R., Orozovich P., Bucardo J. et al. Prevalence and correlates of HIV infection among female sex workers in 2 Mexico–US border cities. J Infect Dis 2008; 197: 72832.
  • 15
    Toussi S. S., Joseph A., Zheng J. H., Dutta M., Santambrogio L., Goldstein H. Short communication: Methamphetamine treatment increases in vitro and in vivo HIV replication. AIDS Res Hum Retroviruses 2009; 25: 111721.
  • 16
    Wood E., Spittal P. M., Small W., Kerr T., Li K., Hogg R. S. et al. Displacement of Canada's largest public illicit drug market in response to a police crackdown. Can Med Assoc J 2004; 170: 15516.
  • 17
    Aitken C., Moore D., Higgs P., Kelsall J., Kerger M. The impact of a police crackdown on a street drug scene: evidence from the street. Int J Drug Pol 2002; 13: 18998.
  • 18
    Des Jarlais D. C., Arasteh K., Perlis T., Hagan H., Heckathorn D. D., McKnight C. et al. The transition from injection to non-injection drug use: long-term outcomes among heroin and cocaine users in New York City. Addiction 2007; 102: 77885.
  • 19
    Bravo M. J., Royuela L., Barrio G., De La Fuente L., Suarez M., Teresa Brugal M. More free syringes, fewer drug injectors in the case of Spain. Soc Sci Med 2007; 65: 17738.